Phase 2 Observer-Blind, Randomized Trial to Evaluate the Immunogenicity and Safety of PanBlok at Three Dose Levels Adjuvanted With a Stable Oil-in-Water Emulsion Compared With PanBlok Without Adjuvant in Healthy Adults Aged 18 to 49 Years

Trial Profile

Phase 2 Observer-Blind, Randomized Trial to Evaluate the Immunogenicity and Safety of PanBlok at Three Dose Levels Adjuvanted With a Stable Oil-in-Water Emulsion Compared With PanBlok Without Adjuvant in Healthy Adults Aged 18 to 49 Years

Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary) ; Adjuvants
  • Indications Influenza A virus infections
  • Focus Therapeutic Use
  • Sponsors Protein Sciences Corporation
  • Most Recent Events

    • 11 Jan 2017 Primary endpoint (The Difference in Seroconversion/Immunogenicity Between rHA Formulated in an oil-in- Water Adjuvant (SE) Compared to a rHA Antigen Alone.) has been met, according to an article published in the Vaccine.
    • 11 Jan 2017 Results published in the Vaccine.
    • 18 Mar 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top